Bolt Biotherapeutics, Inc. (BOLT) 10-Year Financial Performance & Capital Metrics

BOLT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutBolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.Show more

Revenue $8M -2.4%
EBITDA -$71M +4.1%
Net Income -$63M +8.8%
EPS (Diluted) -1.65 +9.8%
Gross Margin 100% +114.7%
EBITDA Margin -926.75% +1.8%
Operating Margin -949.91% +1.8%
Net Margin -820.78% +6.6%
ROE -74.28% -52.6%
ROIC -55.52% -49.1%
Debt/Equity 0.44 +145.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 104.5%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y104.5%

3Y82.75%

TTM-46.88%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM34.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM-419.99%

ROCE

10Y Avg-77.16%

5Y Avg-67.06%

3Y Avg-48.86%

Latest-65.48%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	215K	231K	1.26M	5.73M	7.88M	7.69M
Revenue Growth %	-	-	0.07%	4.45%	3.55%	0.37%	-0.02%
Cost of Goods Sold+	302K	0	40.36M	75.66M	73.12M	61.54M	0
COGS % of Revenue	-	-	174.71%	60.04%	12.76%	7.81%	-
Gross Profit+	-302K	215K	-40.13M	-74.39M	-67.39M	-53.67M	7.69M
Gross Margin %	-	1%	-173.71%	-59.04%	-11.76%	-6.81%	1%
Gross Profit Growth %	-	1.71%	-187.63%	-0.85%	0.09%	0.2%	1.14%
Operating Expenses+	11.63M	31.18M	9.06M	18.39M	22.93M	22.53M	80.74M
OpEx % of Revenue	-	145.04%	39.2%	14.6%	4%	2.86%	10.5%
Selling, General & Admin	2.21M	5.18M	9.06M	18.39M	22.93M	22.53M	18.46M
SG&A % of Revenue	-	24.1%	39.2%	14.6%	4%	2.86%	2.4%
Research & Development	9.42M	26M	40.36M	75.66M	73.12M	61.54M	57.47M
R&D % of Revenue	-	120.94%	174.71%	60.04%	12.76%	7.81%	7.47%
Other Operating Expenses	-153K	0	-40.36M	-75.66M	-73.12M	-61.54M	4.81M
Operating Income+	-11.63M	-30.97M	-49.18M	-92.79M	-90.32M	-76.2M	-73.05M
Operating Margin %	-	-144.04%	-212.91%	-73.64%	-15.77%	-9.67%	-9.5%
Operating Income Growth %	-	-1.66%	-0.59%	-0.89%	0.03%	0.16%	0.04%
EBITDA+	-11.33M	-30.63M	-48.57M	-91.59M	-88.66M	-74.34M	-71.27M
EBITDA Margin %	-	-142.48%	-210.26%	-72.69%	-15.47%	-9.44%	-9.27%
EBITDA Growth %	-	-1.7%	-0.59%	-0.89%	0.03%	0.16%	0.04%
D&A (Non-Cash Add-back)	302K	335K	611K	1.19M	1.67M	1.85M	1.78M
EBIT	-11.59M	-30.97M	-49.18M	-92.79M	-90.32M	-76.2M	-68.24M
Net Interest Income+	0	524K	199K	281K	2.22M	7M	5.25M
Interest Income	193K	524K	199K	281K	2.22M	7M	5.25M
Interest Expense	0	0	0	0	0	0	0
Other Income/Expense	40K	482K	-11.55M	-5.8M	2.22M	7M	9.93M
Pretax Income+	-11.59M	-30.49M	-60.73M	-98.59M	-88.1M	-69.2M	-63.12M
Pretax Margin %	-	-141.8%	-262.89%	-78.25%	-15.38%	-8.79%	-8.21%
Income Tax+	40K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-11.59M	-30.49M	-60.73M	-98.59M	-88.1M	-69.2M	-63.12M
Net Margin %	-	-141.8%	-262.89%	-78.25%	-15.38%	-8.79%	-8.21%
Net Income Growth %	-	-1.63%	-0.99%	-0.62%	0.11%	0.21%	0.09%
Net Income (Continuing)	-11.59M	-30.49M	-60.73M	-98.59M	-88.1M	-69.2M	-63.12M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-5.96	-3.75	-1.99	-2.79	-2.30	-1.83	-1.65
EPS Growth %	-	0.37%	0.47%	-0.4%	0.18%	0.2%	0.1%
EPS (Basic)	-5.96	-3.75	-1.99	-2.79	-2.30	-1.83	-1.65
Diluted Shares Outstanding	1.94M	8.01M	36.25M	37.4M	37.36M	37.81M	38.18M
Basic Shares Outstanding	1.94M	8.01M	36.25M	37.4M	37.36M	37.81M	38.18M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	14.1M	35.9M	25.36M	189.16M	172.75M	105.71M	50.81M
Cash & Short-Term Investments	13.63M	34.83M	22.84M	186.22M	168.89M	102.19M	47.32M
Cash Only	13.63M	34.83M	5.54M	27.38M	9.24M	10.81M	7.21M
Short-Term Investments	0	0	17.3M	158.84M	159.64M	91.38M	40.12M
Accounts Receivable	0	300K	0	200K	0	0	1.17M
Days Sales Outstanding	-	509.3	-	57.94	-	-	55.3
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	0	2.74M	3.86M	3.52M	1.29M
Total Non-Current Assets+	1.88M	12.55M	21.18M	118.56M	55.06M	54.08M	48.82M
Property, Plant & Equipment	1.44M	11.52M	16.38M	30.6M	28.52M	24.08M	24.89M
Fixed Asset Turnover	-	0.02x	0.01x	0.04x	0.20x	0.33x	0.31x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	584K	0	86.91M	23.94M	26.41M	22.88M
Other Non-Current Assets	433K	446K	4.8M	1.04M	2.59M	3.59M	1.04M
Total Assets+	15.97M	48.45M	46.54M	307.72M	227.81M	159.78M	99.63M
Asset Turnover	-	0.00x	0.00x	0.00x	0.03x	0.05x	0.08x
Asset Growth %	-	2.03%	-0.04%	5.61%	-0.26%	-0.3%	-0.38%
Total Current Liabilities+	2.75M	8.66M	11.26M	21.33M	23.12M	20.46M	15.86M
Accounts Payable	892K	2.1M	1.6M	3.57M	3.59M	2.99M	1.51M
Days Payables Outstanding	1.08K	-	14.45	17.24	17.94	17.72	-
Short-Term Debt	0	0	0	2.5M	0	0	0
Deferred Revenue (Current)	0	599K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	0	1.41M	3.78M	7.5M	4.8M	6.67M	4.2M
Current Ratio	5.12x	4.15x	2.25x	8.87x	7.47x	5.17x	3.20x
Quick Ratio	5.12x	4.15x	2.25x	8.87x	7.47x	5.17x	3.20x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	29.16M	85.64M	140.22M	36.27M	33.18M	26.59M	26.58M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	7.09M	9.38M	21.85M	20.22M	17.44M	22.96M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	29.16M	77.58M	130.85M	210K	42K	43K	0
Total Liabilities	31.92M	94.29M	151.49M	57.6M	56.3M	47.04M	42.43M
Total Debt+	40K	10.19M	10.88M	24.36M	22.61M	20.22M	25.21M
Net Debt	-13.59M	-24.64M	5.33M	-3.03M	13.37M	9.41M	18M
Debt / Equity	-	-	-	0.10x	0.13x	0.18x	0.44x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-
Total Equity+	-15.94M	-45.85M	-104.95M	250.12M	171.51M	112.74M	57.2M
Equity Growth %	-	-1.88%	-1.29%	3.38%	-0.31%	-0.34%	-0.49%
Book Value per Share	-8.20	-5.72	-2.90	6.69	4.59	2.98	1.50
Total Shareholders' Equity	-15.94M	-45.85M	-104.95M	250.12M	171.51M	112.74M	57.2M
Common Stock	0	0	0	0	0	1K	0
Retained Earnings	-17.18M	-47.67M	-108.4M	-206.99M	-295.09M	-364.29M	-427.4M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	-321K	-919K	37K	97K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.87M	-26.34M	-47.31M	-57.07M	-76.5M	-69.53M	-61.29M
Operating CF Margin %	-	-122.53%	-204.8%	-45.29%	-13.35%	-8.83%	-7.97%
Operating CF Growth %	-	-1.67%	-0.8%	-0.21%	-0.34%	0.09%	0.12%
Net Income	-11.59M	-30.49M	-60.73M	-98.59M	-88.1M	-69.2M	-63.12M
Depreciation & Amortization	302K	335K	611K	1.19M	1.67M	1.85M	1.78M
Stock-Based Compensation	123K	508K	1.42M	8.5M	9.58M	9.22M	7.41M
Deferred Taxes	0	0	34K	2.76M	0	0	0
Other Non-Cash Items	153K	1.04M	13.64M	8.56M	3.41M	-1.54M	1.08M
Working Capital Changes	1.14M	2.27M	-2.28M	20.51M	-3.06M	-9.86M	-8.44M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	0	0	2.88M	6.68M	2.77M	-3.41M	0
Cash from Investing+	-290K	-508K	-20.59M	-232.2M	57.86M	71.04M	57.58M
Capital Expenditures	-290K	-508K	-3.26M	-2.34M	-1.95M	-206K	-41K
CapEx % of Revenue	-	2.36%	14.12%	1.86%	0.34%	0.03%	0.01%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	-17.33M	-229.86M	59.81M	0	0
Cash from Financing+	19.09M	48.63M	39.6M	311.11M	503K	253K	108K
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	19.13M	0	-1.97M	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-10.16M	-26.85M	-50.57M	-59.4M	-78.46M	-69.73M	-61.33M
FCF Margin %	-	-124.89%	-218.92%	-47.15%	-13.69%	-8.85%	-7.98%
FCF Growth %	-	-1.64%	-0.88%	-0.17%	-0.32%	0.11%	0.12%
FCF per Share	-5.23	-3.35	-1.40	-1.59	-2.10	-1.84	-1.61
FCF Conversion (FCF/Net Income)	0.85x	0.86x	0.78x	0.58x	0.87x	1.00x	0.97x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-135.83%	-41.79%	-48.69%	-74.28%
Return on Invested Capital (ROIC)	-	-	-	-94.37%	-31.36%	-37.23%	-55.52%
Gross Margin	-	100%	-17370.56%	-5904.37%	-1176.37%	-681.39%	100%
Net Margin	-	-14180%	-26289.18%	-7824.68%	-1537.76%	-878.58%	-820.78%
Debt / Equity	-	-	-	0.10x	0.13x	0.18x	0.44x
FCF Conversion	0.85x	0.86x	0.78x	0.58x	0.87x	1.00x	0.97x
Revenue Growth	-	-	7.44%	445.45%	354.68%	37.48%	-2.36%

Frequently Asked Questions

Growth & Financials

Bolt Biotherapeutics, Inc. (BOLT) reported $5.2M in revenue for fiscal year 2024.

Bolt Biotherapeutics, Inc. (BOLT) saw revenue decline by 2.4% over the past year.

Bolt Biotherapeutics, Inc. (BOLT) reported a net loss of $42.7M for fiscal year 2024.

Dividend & Returns

Bolt Biotherapeutics, Inc. (BOLT) has a return on equity (ROE) of -74.3%. Negative ROE indicates the company is unprofitable.

Bolt Biotherapeutics, Inc. (BOLT) had negative free cash flow of $47.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Bolt Biotherapeutics, Inc. (BOLT) 10-Year Financial Performance & Capital Metrics

BOLT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $8M -2.4%
EBITDA -$71M +4.1%
Net Income -$63M +8.8%
EPS (Diluted) -1.65 +9.8%
Gross Margin 100% +114.7%
EBITDA Margin -926.75% +1.8%
Operating Margin -949.91% +1.8%
Net Margin -820.78% +6.6%
ROE -74.28% -52.6%
ROIC -55.52% -49.1%
Debt/Equity 0.44 +145.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 104.5%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y104.5%

3Y82.75%

TTM-46.88%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM34.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM-419.99%

ROCE

10Y Avg-77.16%

5Y Avg-67.06%

3Y Avg-48.86%

Latest-65.48%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	215K	231K	1.26M	5.73M	7.88M	7.69M
Revenue Growth %	-	-	0.07%	4.45%	3.55%	0.37%	-0.02%
Cost of Goods Sold+	302K	0	40.36M	75.66M	73.12M	61.54M	0
COGS % of Revenue	-	-	174.71%	60.04%	12.76%	7.81%	-
Gross Profit+	-302K	215K	-40.13M	-74.39M	-67.39M	-53.67M	7.69M
Gross Margin %	-	1%	-173.71%	-59.04%	-11.76%	-6.81%	1%
Gross Profit Growth %	-	1.71%	-187.63%	-0.85%	0.09%	0.2%	1.14%
Operating Expenses+	11.63M	31.18M	9.06M	18.39M	22.93M	22.53M	80.74M
OpEx % of Revenue	-	145.04%	39.2%	14.6%	4%	2.86%	10.5%
Selling, General & Admin	2.21M	5.18M	9.06M	18.39M	22.93M	22.53M	18.46M
SG&A % of Revenue	-	24.1%	39.2%	14.6%	4%	2.86%	2.4%
Research & Development	9.42M	26M	40.36M	75.66M	73.12M	61.54M	57.47M
R&D % of Revenue	-	120.94%	174.71%	60.04%	12.76%	7.81%	7.47%
Other Operating Expenses	-153K	0	-40.36M	-75.66M	-73.12M	-61.54M	4.81M
Operating Income+	-11.63M	-30.97M	-49.18M	-92.79M	-90.32M	-76.2M	-73.05M
Operating Margin %	-	-144.04%	-212.91%	-73.64%	-15.77%	-9.67%	-9.5%
Operating Income Growth %	-	-1.66%	-0.59%	-0.89%	0.03%	0.16%	0.04%
EBITDA+	-11.33M	-30.63M	-48.57M	-91.59M	-88.66M	-74.34M	-71.27M
EBITDA Margin %	-	-142.48%	-210.26%	-72.69%	-15.47%	-9.44%	-9.27%
EBITDA Growth %	-	-1.7%	-0.59%	-0.89%	0.03%	0.16%	0.04%
D&A (Non-Cash Add-back)	302K	335K	611K	1.19M	1.67M	1.85M	1.78M
EBIT	-11.59M	-30.97M	-49.18M	-92.79M	-90.32M	-76.2M	-68.24M
Net Interest Income+	0	524K	199K	281K	2.22M	7M	5.25M
Interest Income	193K	524K	199K	281K	2.22M	7M	5.25M
Interest Expense	0	0	0	0	0	0	0
Other Income/Expense	40K	482K	-11.55M	-5.8M	2.22M	7M	9.93M
Pretax Income+	-11.59M	-30.49M	-60.73M	-98.59M	-88.1M	-69.2M	-63.12M
Pretax Margin %	-	-141.8%	-262.89%	-78.25%	-15.38%	-8.79%	-8.21%
Income Tax+	40K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-11.59M	-30.49M	-60.73M	-98.59M	-88.1M	-69.2M	-63.12M
Net Margin %	-	-141.8%	-262.89%	-78.25%	-15.38%	-8.79%	-8.21%
Net Income Growth %	-	-1.63%	-0.99%	-0.62%	0.11%	0.21%	0.09%
Net Income (Continuing)	-11.59M	-30.49M	-60.73M	-98.59M	-88.1M	-69.2M	-63.12M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-5.96	-3.75	-1.99	-2.79	-2.30	-1.83	-1.65
EPS Growth %	-	0.37%	0.47%	-0.4%	0.18%	0.2%	0.1%
EPS (Basic)	-5.96	-3.75	-1.99	-2.79	-2.30	-1.83	-1.65
Diluted Shares Outstanding	1.94M	8.01M	36.25M	37.4M	37.36M	37.81M	38.18M
Basic Shares Outstanding	1.94M	8.01M	36.25M	37.4M	37.36M	37.81M	38.18M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	14.1M	35.9M	25.36M	189.16M	172.75M	105.71M	50.81M
Cash & Short-Term Investments	13.63M	34.83M	22.84M	186.22M	168.89M	102.19M	47.32M
Cash Only	13.63M	34.83M	5.54M	27.38M	9.24M	10.81M	7.21M
Short-Term Investments	0	0	17.3M	158.84M	159.64M	91.38M	40.12M
Accounts Receivable	0	300K	0	200K	0	0	1.17M
Days Sales Outstanding	-	509.3	-	57.94	-	-	55.3
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	0	2.74M	3.86M	3.52M	1.29M
Total Non-Current Assets+	1.88M	12.55M	21.18M	118.56M	55.06M	54.08M	48.82M
Property, Plant & Equipment	1.44M	11.52M	16.38M	30.6M	28.52M	24.08M	24.89M
Fixed Asset Turnover	-	0.02x	0.01x	0.04x	0.20x	0.33x	0.31x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	584K	0	86.91M	23.94M	26.41M	22.88M
Other Non-Current Assets	433K	446K	4.8M	1.04M	2.59M	3.59M	1.04M
Total Assets+	15.97M	48.45M	46.54M	307.72M	227.81M	159.78M	99.63M
Asset Turnover	-	0.00x	0.00x	0.00x	0.03x	0.05x	0.08x
Asset Growth %	-	2.03%	-0.04%	5.61%	-0.26%	-0.3%	-0.38%
Total Current Liabilities+	2.75M	8.66M	11.26M	21.33M	23.12M	20.46M	15.86M
Accounts Payable	892K	2.1M	1.6M	3.57M	3.59M	2.99M	1.51M
Days Payables Outstanding	1.08K	-	14.45	17.24	17.94	17.72	-
Short-Term Debt	0	0	0	2.5M	0	0	0
Deferred Revenue (Current)	0	599K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	0	1.41M	3.78M	7.5M	4.8M	6.67M	4.2M
Current Ratio	5.12x	4.15x	2.25x	8.87x	7.47x	5.17x	3.20x
Quick Ratio	5.12x	4.15x	2.25x	8.87x	7.47x	5.17x	3.20x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	29.16M	85.64M	140.22M	36.27M	33.18M	26.59M	26.58M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	7.09M	9.38M	21.85M	20.22M	17.44M	22.96M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	29.16M	77.58M	130.85M	210K	42K	43K	0
Total Liabilities	31.92M	94.29M	151.49M	57.6M	56.3M	47.04M	42.43M
Total Debt+	40K	10.19M	10.88M	24.36M	22.61M	20.22M	25.21M
Net Debt	-13.59M	-24.64M	5.33M	-3.03M	13.37M	9.41M	18M
Debt / Equity	-	-	-	0.10x	0.13x	0.18x	0.44x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-
Total Equity+	-15.94M	-45.85M	-104.95M	250.12M	171.51M	112.74M	57.2M
Equity Growth %	-	-1.88%	-1.29%	3.38%	-0.31%	-0.34%	-0.49%
Book Value per Share	-8.20	-5.72	-2.90	6.69	4.59	2.98	1.50
Total Shareholders' Equity	-15.94M	-45.85M	-104.95M	250.12M	171.51M	112.74M	57.2M
Common Stock	0	0	0	0	0	1K	0
Retained Earnings	-17.18M	-47.67M	-108.4M	-206.99M	-295.09M	-364.29M	-427.4M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	-321K	-919K	37K	97K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.87M	-26.34M	-47.31M	-57.07M	-76.5M	-69.53M	-61.29M
Operating CF Margin %	-	-122.53%	-204.8%	-45.29%	-13.35%	-8.83%	-7.97%
Operating CF Growth %	-	-1.67%	-0.8%	-0.21%	-0.34%	0.09%	0.12%
Net Income	-11.59M	-30.49M	-60.73M	-98.59M	-88.1M	-69.2M	-63.12M
Depreciation & Amortization	302K	335K	611K	1.19M	1.67M	1.85M	1.78M
Stock-Based Compensation	123K	508K	1.42M	8.5M	9.58M	9.22M	7.41M
Deferred Taxes	0	0	34K	2.76M	0	0	0
Other Non-Cash Items	153K	1.04M	13.64M	8.56M	3.41M	-1.54M	1.08M
Working Capital Changes	1.14M	2.27M	-2.28M	20.51M	-3.06M	-9.86M	-8.44M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	0	0	2.88M	6.68M	2.77M	-3.41M	0
Cash from Investing+	-290K	-508K	-20.59M	-232.2M	57.86M	71.04M	57.58M
Capital Expenditures	-290K	-508K	-3.26M	-2.34M	-1.95M	-206K	-41K
CapEx % of Revenue	-	2.36%	14.12%	1.86%	0.34%	0.03%	0.01%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	-17.33M	-229.86M	59.81M	0	0
Cash from Financing+	19.09M	48.63M	39.6M	311.11M	503K	253K	108K
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	19.13M	0	-1.97M	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-10.16M	-26.85M	-50.57M	-59.4M	-78.46M	-69.73M	-61.33M
FCF Margin %	-	-124.89%	-218.92%	-47.15%	-13.69%	-8.85%	-7.98%
FCF Growth %	-	-1.64%	-0.88%	-0.17%	-0.32%	0.11%	0.12%
FCF per Share	-5.23	-3.35	-1.40	-1.59	-2.10	-1.84	-1.61
FCF Conversion (FCF/Net Income)	0.85x	0.86x	0.78x	0.58x	0.87x	1.00x	0.97x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-135.83%	-41.79%	-48.69%	-74.28%
Return on Invested Capital (ROIC)	-	-	-	-94.37%	-31.36%	-37.23%	-55.52%
Gross Margin	-	100%	-17370.56%	-5904.37%	-1176.37%	-681.39%	100%
Net Margin	-	-14180%	-26289.18%	-7824.68%	-1537.76%	-878.58%	-820.78%
Debt / Equity	-	-	-	0.10x	0.13x	0.18x	0.44x
FCF Conversion	0.85x	0.86x	0.78x	0.58x	0.87x	1.00x	0.97x
Revenue Growth	-	-	7.44%	445.45%	354.68%	37.48%	-2.36%

Frequently Asked Questions

Growth & Financials

Bolt Biotherapeutics, Inc. (BOLT) reported $5.2M in revenue for fiscal year 2024.

Bolt Biotherapeutics, Inc. (BOLT) saw revenue decline by 2.4% over the past year.

Bolt Biotherapeutics, Inc. (BOLT) reported a net loss of $42.7M for fiscal year 2024.

Dividend & Returns

Bolt Biotherapeutics, Inc. (BOLT) has a return on equity (ROE) of -74.3%. Negative ROE indicates the company is unprofitable.

Bolt Biotherapeutics, Inc. (BOLT) had negative free cash flow of $47.2M in fiscal year 2024, likely due to heavy capital investments.